Oral Delivery of Large Molecules

About Us

Management Team

Management Team

Dr. Spiros Jamas - CEO

Spiros Jamas is a biotech entrepreneur with over 30 years of senior management experience in the biopharmaceutical industry. He has served as CEO and/or founder of multiple high growth, innovation-driven companies including: AOBiome Therapeutics, Inc., Tempero Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc. and Alpha-Beta Technology, Inc. He has assembled high-performance teams to grow these organizations and led first-in-class R&D programs from early discovery through Investigative New Drug Application (IND) submissions and into advanced clinical development. As founding CEO of AOBiome, he created a leading skin microbiome company that launched the breakthrough skin probiotic AO+ Mist and Mother Dirt Consumer Brand and led the effort to file six IND’s. At Enanta he led the initiation of the Hepatitis C drug development program. Over the course of his career, Dr. Jamas has raised over $300 million in funding from a variety of sources including public and private equity and debt. In addition to his significant experience in building biopharma companies, Dr. Jamas was the Global Healthcare Analyst in the Global Fundamental Strategies group at State Street Global Advisors, the world’s second largest asset management firm. Dr. Jamas obtained a Doctor of Science in Biotechnology from M.I.T. in 1987, a M.Sc. also from M.I.T. in 1983 and a B.Sc. in Chemical Engineering from UMIST, England. He is an author and co-inventor on numerous papers and patents.

Dr. Phillip Schwartz President of R&D and Executive Vice President

Dr. Schwartz has more than twenty years of biotech and pharmaceutical industry experience. He has served as CEO and director of the board of director of Entera since its inception in 2010. Previously he held multiple positions in medical affairs, business development and clinical trial development at Serono and served as manager of clinical affairs at Endo Pharmaceuticals. He served as consultant to more than 20 large biotech and pharmaceutical companies and a number of venture capital firms. Dr Schwartz has multiple publications in tier one peer reviewed journals and has presented papers at numerous international conferences. Dr. Schwartz completed his BA in psychology and architecture at Columbia University. He then studied and worked in neurobiology with Nobel Laureate Professor Torsten Wiesel of the Rockefeller University. After completing his project, Dr. Schwartz studied immunology with Professor Irun Cohen at the Weizmann Institute, receiving his MSc. in 1991. In 1997 Dr. Schwartz received his Ph.D. in neurobiology/development/oncology from Harvard Medical School.

Dr. Hillel Galitzer – COO

Dr. Galitzer has more than ten years of experience in medical research and molecular biology and was mentored by two world renowned researchers in the field of PTH and calcium regulation. He has served as COO since February 2014, and on partial time as Director of Scientific Development since July 2010. Between August 2010 and February 2014 Dr. Galitzer was an analyst and COO for Hadasit Bio Holdings Ltd., a publicly traded company on the TASE and OTC markets. Dr. Galitzer is the co-founder and Chief Operating Officer of Optivasive Inc. He has written numerous publications in tier one peer reviewed articles and has lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, and his M.B.A. from Bar-Ilan University in Israel.

Dr. Arthur Santora - CMO

Dr. Santora has more than 30 years of experience in the biotech industry. He has spent the majority of his career in the clinical research team at Merck, where he was the lead clinical research physician responsible for much of the clinical development of Fosamax® (alendronate sodium), one of the world's most prescribed osteoporosis treatments. Dr. Santora was closely involved in the clinical development of Merck’s once-weekly Fosamax Plus D (alendronate sodium/ vitamin D3 combination tablets), the first drug/vitamin combination tablet in the US. His position when he retired from Merck in 2017 was as Scientific Associate Vice President of Clinical Research, where he was directly responsible for the technical and scientific support for all clinical research of Fosamax/Fosamax plus D and contributed to the development of many other osteoporosis and endocrine marketed and investigational drugs. Dr. Santora started his career at the FDA after completing an Endocrinology and Metabolism fellowship at the NIH Clinical Center in Bethesda, MD. He received an M.D. and Ph.D. in biochemistry from Emory University in Atlanta.

Dana Yaacov-Garbeli, CPA, - Israel CFO.

Mrs. Yaacov-Garbeli brings over 11 years of finance and accounting experience, including more than 9 years of experience at a Big-4 accounting firm, PwC. She has expertise in financial planning, operations, management, and strategy with extensive experience in external and internal audit for public multinational clients under US GAAP, IFRS and PCAOB standards. She is currently a Partner at A2Z-Finance, where she served as an outsourced CFO to both private and publicly traded companies and provided additional consulting and accounting services.  At PwC she served as the Lead Senior Manager on audits of both public and privately held multi-location companies in Israel, US and Europe, mainly in pharmaceuticals, biotech, holdings, industrial products, retail and high-tech sectors.  She received an MBA from The College of Management Academic Studies in Israel, with a concentration in financial management, and is a Certified Public Accountant. 

Miranda Toledano Chief Financial Officer, Chief Business Officer, Head of Corporate Strategy

Ms. Toledano most recently served as Chief Operating Officer, Chief Financial Officer and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totalling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma. Ms. Toledano currently serves as a member of our board of directors as well as a member of the board of directors of Compass Therapeutics (Nasdaq: CMPX), Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.